[1]Patent:US4665074,1987,A
Title: Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.
Journal: Journal of medicinal chemistry 20120913
Title: Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
Journal: Bioorganic & medicinal chemistry letters 20101101
Title: Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Journal: Journal of medicinal chemistry 20080925
Title: Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model.
Journal: Journal of biomolecular screening 20060801
Title: Microsphere-based protease assays and screening application for lethal factor and factor Xa.
Journal: Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501
Title: Structural basis for the activity of drugs that inhibit phosphodiesterases.
Journal: Structure (London, England : 1993) 20041201
Title: Identification of purine inhibitors of phosphodiesterase 7 (PDE7).
Journal: Bioorganic & medicinal chemistry letters 20040607
Title: Sertoli cell junctional proteins as early targets for different classes of reproductive toxicants.
Journal: Reproductive toxicology (Elmsford, N.Y.) 20040501
Title: Zardaverine and aerosolised iloprost in a model of acute respiratory failure.
Journal: The European respiratory journal 20030801
Title: Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents.
Journal: Journal of medicinal chemistry 20030508
Title: Crystal structure of phosphodiesterase 4D and inhibitor complex(1).
Journal: FEBS letters 20021023
Title: Novel selective PDE4 inhibitors. 1. Synthesis, structure-activity relationships, and molecular modeling of 4-(3,4-dimethoxyphenyl)-2H-phthalazin-1-ones and analogues.
Journal: Journal of medicinal chemistry 20010802
Title: Evidence that the anti-spasmogenic effect of the beta-adrenoceptor agonist, isoprenaline, on guinea-pig trachealis is not mediated by cyclic AMP-dependent protein kinase.
Journal: British journal of pharmacology 20010801
Title: R.T. Schermuly, H. Leuchte, H.A. Ghofrani, et al. Zardaverine and aerosolised iloprost in a model of acute respiratoryfailure. ERJ, 2003 ,22 (2): 342-347.
Title: D. Ukena, K. Rentz, C. Reiber, et al. Effects of the mixed phosphodiesterase III/IV inhibitor, zardaverine, on airway function in patients with chronic airflow obstruction. Respiratory Medicine.1995, 89 ( 6) : 441-444.
Title: Schade FU, Schudt C. The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages. European Journal of Pharmacology.1993, 230(1):9-14.
